21 September 2022 - NICE is unable to make a recommendation about the use in the NHS of vedolizumab for the treatment of patients with chronic refractory pouchitis after surgery for ulcerative colitis. 

This is because Takeda did not provide an evidence submission. Takeda has confirmed that the technology will not be launched in the UK for this indication.

Read NICE technology appraisal